Comparison of Efficacy and Safety Psoralen Combined With Ultraviolet A (PUVA) Vs Tofacitinib in the Treatment of Generalized Vitiligo.

NCT07055529 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

NOT_YET_RECRUITING

Status

64

Enrollment

OTHER_GOV

Sponsor class

Conditions

Vitiligo, Generalized

Interventions

DRUG: Group A recieving PUVA therapy
DRUG: Group B receiving Tablet Tofacitinib

Sponsor

Hayat Abad Medical Complex, Peshawar